Read by QxMD icon Read


Yuting Zhang, Lusheng Li, Ping Liang, Xuan Zhai, Yingliang Li, Yudong Zhou
AIM: To identify differentially expressed microRNAs in medulloblastoma, and to investigate their biological function. MATERIAL AND METHODS: Differentially expressed microRNAs were identified using gene chips, and significantly different microRNAs were selected for verification using real time quantitative PCR. Potential target genes and their biological pathways were predicted by bioinformatics software. RESULTS: Our analysis identified two microRNAs, hsa-miR-208a-3p and hsa-miR-1207-5p, which were significantly downregulated in medulloblastoma...
2018: Turkish Neurosurgery
Paul A Northcott, David T W Jones, Marcel Kool, Giles W Robinson, Richard J Gilbertson, Yoon-Jae Cho, Scott L Pomeroy, Andrey Korshunov, Peter Lichter, Michael D Taylor, Stefan M Pfister
The division of medulloblastoma into different subgroups by microarray expression profiling has dramatically changed our perspective of this malignant childhood brain tumour. Now, the availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup. The implications of these findings for the management of patients are readily apparent, pinpointing previously unappreciated diagnostic and therapeutic targets. In this Review, we summarize the 'explosion' of data emerging from the application of modern genomics to medulloblastoma, and in particular the recurrent targets of mutation in medulloblastoma subgroups...
December 2012: Nature Reviews. Cancer
Christian Carrie, Xavier Muracciole, Frédéric Gomez, Jean-Louis Habrand, Mohamed Benhassel, Martine Mege, Marc Mahé, Philippe Quetin, Jean Philippe Maire, Françoise Soum, Marie Helene Baron, Pierre Clavere, Sophie Chapet, Zineb Gaci, Helene Kolodie, Philippe Maingon, Bernard Vie, Valérie Bernier, Claire Alapetite, Sylvette Hoffstetter, Jacques Grill, Frédéric Lafay
PURPOSE: Between December 1998 and October 2001, patients <19 years old were treated for standard-risk medulloblastoma according to the Medulloblastome-Société Française d'Oncologie Pédiatrique 1998 (M-SFOP 98) protocol. Patients received hyperfractionated radiotherapy (36 Gy in 36 fractions) to the craniospinal axis, a boost with conformal therapy restricted to the tumor bed (to a total dose of 68 Gy in 68 fractions), and no chemotherapy. Records of craniospinal irradiation were reviewed before treatment start...
November 1, 2005: International Journal of Radiation Oncology, Biology, Physics
No abstract text is available yet for this article.
September 1962: Ceskoslovenská Neurologie
J Cervos-Navarro, F Matakas
No abstract text is available yet for this article.
November 1970: Neuro-Chirurgie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"